Loading the section…

XENE: financial statements from SEC — TradeAlmanac

XENE

Xenon Pharmaceuticals Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	0	0	0	8M	0	0
Research and development	89M	77M	75M	61M	57M	50M
Selling, general and administrative	24M	19M	19M	19M	17M	19M
Operating expenses	112M	96M	94M	80M	74M	69M
Operating income	−112M	−96M	−94M	−73M	−74M	−69M
Pre-tax income	−105M	−90M	−85M	−65M	−63M	−58M
Income tax	−3M	677,000	−626,000	427,000	−320,000	−333,000
Net income	−102M	−91M	−85M	−65M	−63M	−58M
Earnings per share	−1.17	−1.15	−1.07	−0.83	−0.81	−0.75
Earnings per share, diluted	−1.17	−1.15	−1.07	−0.83	−0.81	−0.75
Weighted average shares	87M	79M	79M	79M	78M	78M
Weighted average shares, diluted	87M	79M	79M	79M	78M	78M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	546M	199M	105M	135M	117M	143M	88M	137M
Short-term investments	549M	350M	358M

Cash flow

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Operating cash flow	−89M	—	—	−62M	—	—
Depreciation and amortisation	587,000	—	—	659,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator